Neurent Medical Publishes Positive RCT Results for NEUROMARK System in Chronic Rhinitis

Neurent Medical Publishes Positive RCT Results for NEUROMARK System in Chronic Rhinitis

By, Admin 25 February 2026

Neurent Medical has published positive results from a randomized controlled trial (RCT) evaluating its NEUROMARK® System in the International Forum of Allergy & Rhinology.

The study found that treatment with the NEUROMARK System was statistically superior to sham control in improving nasal symptoms and quality-of-life measures in patients with chronic rhinitis.

Study Design: Rigorous, Sham-Controlled Trial

The prospective, multicenter, single-blind superiority RCT enrolled 132 participants, randomized to:

  • Active treatment with the NEUROMARK System
  • Sham control

Primary Endpoint

The primary endpoint was the reflective Total Nasal Symptom Score (rTNSS) responder rate at 90 days.

Secondary Endpoints Included:

  • Postnasal drip
  • Chronic cough
  • Nasal Obstruction Symptom Evaluation (NOSE) score
  • mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ)
  • Patient Health Questionnaire-9 (PHQ-9)

Key Findings

The trial met its primary endpoint and demonstrated clear superiority over sham control.

rTNSS Responder Rate (Primary Endpoint)

  • 73.3% in the active treatment group
  • 35.0% in the sham group
  • p < 0.001

Additional Outcomes

Participants treated with NEUROMARK experienced significantly greater improvements in:

  • Overall nasal symptoms (rTNSS)
  • Postnasal drip
  • Chronic cough
  • NOSE score
  • mini-RQLQ
  • PHQ-9

Responder rates for both NOSE and mini-RQLQ were significantly higher in the active treatment arm.

Targeting the Root Cause of Symptoms

The NEUROMARK System is an impedance-controlled radiofrequency ablation device designed to deliver multipoint energy to the posterior nasal nerve region.

By targeting neural pathways that drive chronic rhinitis symptoms, the device aims to:

  • Reduce excessive nasal discharge
  • Improve obstruction
  • Address persistent symptoms that remain despite medical therapy

The therapy is positioned as a minimally invasive, non-surgical treatment option for appropriate patients.

Why This Matters?

Chronic rhinitis significantly affects quality of life, and many patients do not achieve adequate symptom control with standard medical management.

A sham-controlled RCT demonstrating superiority provides high-level clinical evidence supporting posterior nasal nerve ablation as a viable therapeutic option.

For Neurent Medical, the publication strengthens the clinical foundation for broader adoption of the NEUROMARK System in the treatment of chronic rhinitis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!